Drug intelligence / Profile preview

C-Tb + Tuberculin PPD RT 23 SSI

Development stage: Unknown
Lead developer: Statens Serum Institut
Administration: Intradermal

Overview

C-Tb + Tuberculin PPD RT 23 SSI appears to be a combination of two diagnostic agents used for tuberculosis (TB) testing. Tuberculin PPD RT 23 SSI is a purified protein derivative prepared from a culture of seven selected strains of Mycobacterium tuberculosis. It is used in the Mantoux test to help diagnose tuberculosis infection. One dose (0.1 mL) contains 2 Tuberculin Units, equal to 0.04 μg of Tuberculin PPD RT 23. C-Tb is likely a newer diagnostic agent being compared to Tuberculin PPD RT 23 SSI in clinical trials for TB diagnosis.

Targets

ESAT-6/CFP-10-specific T-cell receptorT-cell receptor-peptide-MHC II complex (TCR-pMHC II)

Beyond the preview

Go deeper on C-Tb + Tuberculin PPD RT 23 SSI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-Tb + Tuberculin PPD RT 23 SSI.

Explore the full profile